logo-loader
HealthPharma & Biotech
Faron Pharmaceuticals Ltd

Faron Pharmaceuticals gains some early understanding of phase III trial data

The company is taking a closer look at the results from its INTEREST study

clinical trial written on a pad
Detailed analysis of the data and testing of product batches still needs to be conducted

Faron Pharmaceuticals Ltd (LON:FARN) said early follow-up analysis of its unsuccessful phase III clinical trial suggests the treatment did not produce the expected interferon-beta bioactivity seen in the phase I/II study.

The company said it is still too early to understand why this was the case, but it cited a number of possible causes. It is investigating the formulation of the drug, its administration and deactivation. 

READ: Faron Pharma assesses options after phase III disappointment

"Further detailed analysis of the data and testing of product batches still needs to be conducted, and therefore there is no guarantee that this will ultimately prove to be conclusive or, of the resultant implications of that analysis," Faron said in a short statement.

 

Quick facts: Faron Pharmaceuticals Ltd

Price: £1.07

Market: AIM
Market Cap: £41.91 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Faron Pharmaceuticals Ltd named herein, including the promotion by the Company of Faron Pharmaceuticals Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

A 'thrilling' year ahead for Faron Pharmaceuticals with Phase III Traumakine...

Markku Jalkanen, chief executive at Faron Pharmaceuticals Oy (LON:FARN), caught up with Proactive following their £15mln funding aimed at accelerating the development of its two lead products. Jalkanen says the funds will allow them to prepare the way to market for Traumakine, a treatment...

on 21/2/18

2 min read